Halozyme Therapeutics, Inc. (HALO)

NMS – Real vaqt narxi. Valyuta: USD

101.80

-0.82 (-0.80%)

Yopilishda: Aug 12, 2026, 3:59 PM EDT

101.79

0.00 (0.00%)

Bozordan keyin: Aug 12, 2026, 4:10 PM EDT

07.08.2026

Halozyme's Q2 Earnings Beat Estimates, 2026 Outlook Raised, Stock Up

HALO's Q2 earnings and revenues surpass estimates, fueled by higher royalties and product sales. The company raises its 2026 outlook.

07.08.2026

Halozyme Therapeutics Q2 Earnings Call Highlights

Halozyme Therapeutics NASDAQ: HALO reported record second-quarter revenue and raised its full-year outlook, citing growth in royalty income from its ENHANZE drug-delivery platform, contributions from newer product launches and revenue from newly signed collaboration agreements.

06.08.2026

Halozyme Therapeutics, Inc. (HALO) Q2 2026 Earnings Call Transcript

06.08.2026

Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics

Although the revenue and EPS for Halozyme Therapeutics (HALO) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

06.08.2026

Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates

Halozyme Therapeutics (HALO) came out with quarterly earnings of $2.28 per share, beating the Zacks Consensus Estimate of $1.82 per share. This compares to earnings of $1.54 per share a year ago.

06.08.2026

HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE

Total Revenue Increased 48% YOY to $481 million Royalty Revenue Increased 50% YOY to $308 million Raises 2026 Financial Guidance Ranges: Total Revenue of $1.835 - $1.910 billion, YOY Growth of 31% - 37% Royalty Revenue of $1.220 - $1.245 billion, YOY Growth of 41% - 43% Adjusted EBITDA of $1.225 - $1.280 billion, YOY Growth of 86% - 95% 1 Non-GAAP Diluted EPS of $8.65 - $9.00, YOY Growth of 108% - 117% 1 Signed Five New ENHANZE ® and Hypercon ™ Collaboration Agreements YTD 2026, Exceeding Goal of Three for Full Year 2026 SAN DIEGO, Aug. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the second quarter ended June 30, 2026, and provided an update on its recent corporate activities. "We delivered another quarter of strong performance, with multiple proof points demonstrating the attractive features of ENHANZE as a compounding platform engine: repeatability of success, scalability, diversification and durability of revenues," said Dr. Helen Torley, President and Chief Executive Officer.

Videolar

No Data

There is no data to display

Reytinglar oshishi / pasayishi

Ticker	Tashkilot	Reyting o‘zgarishi	Maqsadli narx	Sana
HALO	Leerink Partners	Outperform	undefined >> $110	August 7th 2026

Press-relizlar

06.08.2026

Halozyme Therapeutics, Inc. (HALO)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Halozyme Therapeutics, Inc. (HALO)

Halozyme's Q2 Earnings Beat Estimates, 2026 Outlook Raised, Stock Up

Halozyme Therapeutics Q2 Earnings Call Highlights

Halozyme Therapeutics, Inc. (HALO) Q2 2026 Earnings Call Transcript

Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics

Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates

HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE

Videolar

No Data

Reytinglar oshishi / pasayishi

Press-relizlar

HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE

Halozyme's Q2 Earnings Beat Estimates, 2026 Outlook Raised, Stock Up

Halozyme Therapeutics Q2 Earnings Call Highlights

Halozyme Therapeutics, Inc. (HALO) Q2 2026 Earnings Call Transcript

Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics

Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates

HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE

Videolar

No Data

Reytinglar oshishi / pasayishi

Press-relizlar

HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE

Search stocks

Halozyme Therapeutics, Inc. (HALO)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Halozyme Therapeutics, Inc. (HALO)

Halozyme's Q2 Earnings Beat Estimates, 2026 Outlook Raised, Stock Up

Halozyme Therapeutics Q2 Earnings Call Highlights

Halozyme Therapeutics, Inc. (HALO) Q2 2026 Earnings Call Transcript

Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics

Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates

HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE

Videolar

No Data

Reytinglar oshishi / pasayishi

Press-relizlar

HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE

Halozyme's Q2 Earnings Beat Estimates, 2026 Outlook Raised, Stock Up

Halozyme Therapeutics Q2 Earnings Call Highlights

Halozyme Therapeutics, Inc. (HALO) Q2 2026 Earnings Call Transcript

Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics

Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates

HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE

Videolar

No Data

Reytinglar oshishi / pasayishi

Press-relizlar

HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE